Commercialization: Page 26

PharmaVoice Team/PharmaVoice

Red Jacket Andrea McGonigle

Andrea McGonigle For Being a Health Technology Convener Title: National Managing Director, Health and Life Sciences Company: Microsoft Education: BS, University of Phoenix Family: Husband, Anthony; two children, Haley, 16, and Patrick, 12 Hobbies: Kids sports, Broadway shows, blogging, and travel...
By PharmaVoice Team • Aug. 1, 2018
PharmaVoice Team/PharmaVoice

Red Jacket Lynn O'Connor Vos

Lynn O’Connor Vos For Creating a Greater Impact in the Nonprofit Industry Title: President and CEO Company: Muscular Dystrophy Association Education: BS and BSRN, Alfred University Awards/Honors: HBA Woman of the Year Associations: Healthcare Businesswomen’s Association Social Media: Tweet: @lynn...
By PharmaVoice Team • Aug. 1, 2018
PharmaVoice Team/PharmaVoice

Red Jacket Melinda Richter

Melinda Richter For Empowering the Extraordinary Title: Global Head Company: Johnson & Johnson Innovation, JLABS Education: B Commerce, University of Saskatchewan; MBA, INSEAD Family: Victor Casale, her partner, her biggest fan and inspiration Hobbies: Heli-boarding in Alaska, diving with sha...
By PharmaVoice Team • Aug. 1, 2018
PharmaVoice Team/PharmaVoice

Reading List

On the Book Shelf What are they reading? The PharmaVOICE 100 are curious and always in pursuit of continual learning to expand their knowledge and hone their leadership strategies. This is sampling of their readlng list. Download PDF
By PharmaVoice Team • Aug. 1, 2018
PharmaVoice Team/PharmaVoice

Upfront

Bayer Unites with Advocacy Groups to Raise Awareness about Colorectal Cancer Bayer has announced another year of its partnership with patient advocacy organizations Colorectal Cancer Alliance and Fight Colorectal Cancer. Bayer is touring with the alliance on the national Big Colon Tour in 2018 to...
By PharmaVoice Team • June 1, 2018
PharmaVoice Team/PharmaVoice

HealthTech

Caffeine-Containing Biocompatible Gels for Drug Delivery Trend Watch: Gels and AR advances create new methods of disease treatment, monitoring and diagnosis Researchers at MIT may use caffeine to jump start their day, but they are also working on using it as a catalyst for a biocompatible polymer...
By PharmaVoice Team • June 1, 2018
PharmaVoice Team/PharmaVoice

Transformation: Is the Industry Ready?

Although the pharma industry scored pretty low on a McKinsey scale of digital maturity, there is evidence that it is moving — perhaps only incrementally — toward a digital transformation that can streamline processes, generate collaboration, and coordinate data collection. The pharma sector, not ...
By PharmaVoice Team • June 1, 2018
PharmaVoice Team/PharmaVoice

Client-Agency Relationships 101

We could write a book — and many have — on all of the necessary ingredients to create a successful partnership in the life-sciences space of client-agency relationships. But instead, we’ve asked our thought leaders to focus on three vital issues: what is needed to build and maintain strong relati...
By Robin Robinson • June 1, 2018
PharmaVoice Team/PharmaVoice

SHOWCASE: Clinical Trial Solutions: Digital Technology Changing the Face of Clinical Trials

Greater investment in R&D and a growing number of clinical trials combined with accelerated demand for automated solutions are contributing to a rapidly expanding contract research organization (CRO) market and changing the face of clinical trials. According to some estimates, the CRO market ...
By PharmaVoice Team • June 1, 2018
PharmaVoice Team/PharmaVoice

The Future of Blockchain in Clinical Research

Imagine this: a group of pre-identified, pre-screened patients are remotely enrolled in a clinical trial, their private health records accessed and validated instantaneously upon consent. The investigative product is traced from inception to consumption by each individual patient; ensuring qualit...
By Julie Ross • June 1, 2018
PharmaVoice Team/PharmaVoice

The Transformational Power of Sharing

Decades of progress in information technology reveal, however, that as individuals and in the collective, we constantly struggle to find balance between the benefits of sharing and our desire to keep control. The mainframe computer was cheered as it enabled a corporation to share information that...
By Beenu Kapoor • June 1, 2018
PharmaVoice Team/PharmaVoice

Build a Road, Not a Roadblock — What Sites Want Sponsors To Know

Their message is loud and clear — technology has the potential to be a site’s best friend, but it’s often a roadblock instead. That’s just one of the many insights learned from the sites who participated in a thoughtful panel discussion focused on how they feel about the past, present, and future...
By Claire Sears • June 1, 2018
PharmaVoice Team/PharmaVoice

Moving Beyond Risk-based Monitoring: Improving Quality and Performance with Real-time Management

Risk-based monitoring (RBM) in clinical trials has long been touted as a more proactive way to reduce risk and improve data quality. But the current generation of risk monitoring tools and processes lack the transparency and integration needed to support a level of proactive risk-based management...
By Brion Regan • June 1, 2018
PharmaVoice Team/PharmaVoice

RWE Continues to Shape the Future Clinical Research Landscape

The increasing availability of big data is creating a shift in the clinical research landscape — from trial planning to late-phase — allowing for clinical research professionals to make intelligent, strategic decisions based on real-world evidence (RWE), which is derived from the aggregation and ...
By Jim Carroll • June 1, 2018
PharmaVoice Team/PharmaVoice

Transforming the Life-Science and Healthcare Workforce

In today’s rapidly changing market, organizations and workforce experts alike are trying to determine how the future of work will transform. However, most professionals operate from the perspective of their individual scope of responsibility, which often leads to narrow perspectives that may solv...
By Kevin D. Duffy • June 1, 2018
PharmaVoice Team/PharmaVoice

Community-Based Clinical Trials — The New "Virtual"

Long recruitment timelines and under-performing sites are the most frequently discussed topics in the clinical trials sector. With actual recruitment timelines double the planned expectations, at least 39% of sites under-enroll and 11% of sites fail to enroll a single patient1, new technological ...
By Dr. Graham Wylie • June 1, 2018
PharmaVoice Team/PharmaVoice

When Patients Control Their Data, Clinical Researchers Win

From a young age, we learn to share, but when it comes to the collection and management of clinical research data, the opposite is more often true. Then why is the question still being asked whether patient data should be shared and accessible by patients themselves? The journey towards bettermen...
By Anthony Costello • June 1, 2018
PharmaVoice Team/PharmaVoice

Is Your eClinical System a Mixed Tape or a Playlist?

Just a decade ago, the most advanced option for listening to music at home was a large stereo system made up of a jumble of separate components, all with specific functions, from a half-dozen brands. Not only were these stereo systems bulky they were also expensive, complex to set up and run, onl...
By James Streeter • June 1, 2018
PharmaVoice Team/PharmaVoice

AI and the Cloud: Changing the Clinical Trial Experience

It doesn’t take a crystal ball to see that there are a number of exciting life-science industry trends that will profoundly influence clinical trial solutions in the years to come. Chief among them are: Patient engagement and patient centricity will be king, driving digital transformation with Io...
By Karim Damji • June 1, 2018
PharmaVoice Team/PharmaVoice

Pediatric Drug Development: Regulatory Updates to Know

All applications for marketing authorization for new medicines must include the results of studies in children as described in the pediatric plan, unless the medicine is exempt because of a deferral or waiver. Pediatric legislation internationally has led to better medicines for children, but gap...
By Dr. Martine Dehlinger-Kremer • June 1, 2018
PharmaVoice Team/PharmaVoice

Rare Disease Studies: Patient-Focused Approaches

The National Organization for Rare Disorders (NORD) indicates that there are approximately 7,000 medical conditions that qualify for a rare disease designation. In the United States, this is defined as an affected population with a prevalence of fewer than 200,000 patients. Because there is a gre...
By Bruce Smith • June 1, 2018
PharmaVoice Team/PharmaVoice

GoBoldly: A Reputation-Enhancing Effort

We’ve all seen the commercials. They feature patients living with serious diseases and the researchers working to develop innovative therapies. These ads focus on the science and the breakthroughs being made in medicine. They end with what looks like a genetic analysis giving way to the words Ame...
By Denise Myshko • June 1, 2018
PharmaVoice Team/PharmaVoice

Speak Out

Understanding The Why Applying health psychology to deliver effective patient support As a health and clinical psychologist, I’ve spent the last ten years helping the healthcare industry address the self-management needs of patients living with long-term conditions. For the most part, this work h...
By Kate Perry • June 1, 2018
PharmaVoice Team/PharmaVoice

Letter from the Editor

Riding the AI Wave It would be hard to identify a hotter trend right now than artificial intelligence and machine learning — a trend 60 years in the making since John McCarthy coined the term AI while leading a Dartmouth Summer Research Project. Merriam-Webster defines AI as: a branch of computer...
By Taren Grom • May 1, 2018
PharmaVoice Team/PharmaVoice

Marketing Integration

The pharmaceutical industry has been employing cross-functional teams to improve processes across business silos for quite sometime, but the ongoing shift in healthcare markets and the increasing complexity of drug commercialization has created an environment where cross-functional alignment has ...
By Robin Robinson • May 1, 2018